Track Bristol-Myers Squibb's accounts payable ($4.2B) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), BMY shows a accounts payable of $4.2B. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BMY's accounts payable is now $4.2B (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Bristol-Myers Squibb is outperforming or lagging.
Tracking BMY's accounts payable over time shows whether Bristol-Myers Squibb is scaling, shrinking, or reshaping that part of the business. The current reading is $4.2B In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this accounts payable page, Stockcircle has Bristol-Myers Squibb's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $4.2B) with ownership activity and broader fundamentals.
Bristol-Myers Squibb's accounts payable is $4.2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.